| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2021-09-15 |
| タイトル |
|
|
タイトル |
Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease: Japanese Guideline on the Management of Asymptomatic Hyperuricemia |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Cardio-renal continuum |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
CARES study |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Urate-lowering agent |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Uric acid transporter |
| キーワード |
|
|
主題Scheme |
Other |
|
主題 |
Xanthine oxidase |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cardio-renal continuum |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
CARES study |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Urate-lowering agent |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Uric acid transporter |
| キーワード |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Xanthine oxidase |
| 資源タイプ |
|
|
資源タイプ |
journal article |
| 著者 |
久留, 一郎
李, 佩俐
三明, 淳一朗
Mahati, Endang
桑原, 政成
Bahrudin, Udin
二宮, 治明
Taufiq, Fikri
Mahati, Endang
Maharani, Nani
Utami, Sulistiyati Bayu
Kuwabara, Masanari
Bahrudin, Udin
|
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Pharmacology, Tottori University Faculty of Medicine |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Physiology, Faculty of Medicine, Sultan Agung Islamic University |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Pharmacology and Therapy, Faculty of Medicine, Diponegoro University |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Pharmacology and Therapy, Faculty of Medicine, Diponegoro University |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Intensive Care Unit and Department of Cardiology, Toranomon Hospital |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Cardiology and Vascular Medicine, Faculty of Medicine, Diponegoro University |
| 著者所属（英） |
|
|
言語 |
en |
|
値 |
Department of Biological Regulation, Tottori University Faculty of Medicine |
| 抄録 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Serum uric acid (UA) is taken up by endothelial cells and reduces the level of nitric oxide (NO) by inhibiting its production and accelerating its degradation. Cytosolic and plasma xanthine oxidase (XO) generates superoxide and also decreases the NO level. Thus, hyperuricemia is associated with impaired endothelial function. Hyperuricemia is often associated with vascular diseases such as chronic kidney disease (CKD) and cardiovascular disease (CVD). It has long been debated whether hyperuricemia is causally related to the development of these diseases. The 2020 American College of Rheumatology Guideline for the Management of Gout (ACR2020) does not recommend pharmacological treatment of hyperuricemia in patients with CKD/CVD. In contrast, the Japanese Guideline on Management of Hyperuricemia and Gout (JGMHG), 3rdedition, recommends pharmacological treatment of hyperuricemia in patients with CKD. In a FREED study on Japanese hyperuricemic patients with CVD, an XO inhibitor, febuxostat, improved the primary composite endpoint of cerebro-cardio-renovascular events, providing a rationale for the use of urate-lowering agents (ULAs). Since a CARES study on American gout patients with CVD treated with febuxostat revealed increased mortality, ACR2020 recommends switching to different ULAs. However, there was no difference in the mortality of Japanese patients between the febuxostat-treated group and the placebo or allopurinol-treated groups in either the FEATHER or FREED studies. |
| 書誌情報 |
CIRCULATION JOURNAL
en : CIRCULATION JOURNAL
巻 85,
号 2,
p. 130-138,
発行日 2021-02
|
| 出版者 |
|
|
出版者 |
THE JAPANESE CIRCULATION SOCIETY |
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
13469843 |
| DOI |
|
|
関連タイプ |
isIdenticalTo |
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1253/circj.cj-20-0406 |
| 権利 |
|
|
権利情報 |
© 2021 THE JAPANESE CIRCULATION SOCIETY. This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license. https://creativecommons.org/licenses/by-nc-nd/4.0/ |
| 情報源 |
|
|
|
関連名称 |
Hisatome Ichiro, Li Peili, Miake Junichiro, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease -Japanese Guideline on the Management of Asymptomatic Hyperuricemia-. CIRCULATION JOURNAL. 2021. 85(2). 130-138. doi:10.125 |
| 関連サイト |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
https://www.jstage.jst.go.jp/article/circj/85/2/85_CJ-20-0406/_article/-char/ja/ |
|
|
関連名称 |
https://www.jstage.jst.go.jp/article/circj/85/2/85_CJ-20-0406/_article/-char/ja/ |
| 著者版フラグ |
|
|
出版タイプ |
VoR |
| EISSN |
|
|
値 |
13474820 |
cj85(2)_130.pdf (1.1 MB)
